CN Patent

CN117881399A — 治疗粒线体相关病症的方法

Assigned to Levis Pharmaceutical Co ltd · Expires 2024-04-12 · 2y expired

What this patent protects

本文公开治疗方法，包括向有需要的受试者施用治疗有效量的5‑[(2,4‑二硝基苯氧基)甲基]‑1‑甲基‑2‑硝基‑1H‑咪唑或其药学上可接受的盐。5‑[(2,4‑二硝基苯氧基)甲基]‑1‑甲基‑2‑硝基‑1H‑咪唑可用于治疗粒线体相关病症或病状，包括肥胖症、糖尿病、高血压、心血管疾病和肝病。

USPTO Abstract

本文公开治疗方法，包括向有需要的受试者施用治疗有效量的5‑[(2,4‑二硝基苯氧基)甲基]‑1‑甲基‑2‑硝基‑1H‑咪唑或其药学上可接受的盐。5‑[(2,4‑二硝基苯氧基)甲基]‑1‑甲基‑2‑硝基‑1H‑咪唑可用于治疗粒线体相关病症或病状，包括肥胖症、糖尿病、高血压、心血管疾病和肝病。

Drugs covered by this patent

Patent Metadata

Patent number
CN117881399A
Jurisdiction
CN
Classification
—
Expires
2024-04-12
Drug substance claim
No
Drug product claim
No
Assignee
Levis Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.